158 related articles for article (PubMed ID: 38190082)
1. Anti-pan-neurofascin nodopathy: cause of fulminant neuropathy.
Acerra GM; Bevilacqua L; Noioso CM; Valle PD; Serio M; Vinciguerra C; Piscosquito G; Toriello A; Vegezzi E; Gastaldi M; Barone P; Iovino A
Neurol Sci; 2024 Apr; 45(4):1755-1759. PubMed ID: 38190082
[TBL] [Abstract][Full Text] [Related]
2. Growing Spectrum of Autoimmune Nodopathies.
Gupta P; Mirman I; Shahar S; Dubey D
Curr Neurol Neurosci Rep; 2023 May; 23(5):201-212. PubMed ID: 37014546
[TBL] [Abstract][Full Text] [Related]
3. Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy.
Stengel H; Vural A; Brunder AM; Heinius A; Appeltshauser L; Fiebig B; Giese F; Dresel C; Papagianni A; Birklein F; Weis J; Huchtemann T; Schmidt C; Körtvelyessy P; Villmann C; Meinl E; Sommer C; Leypoldt F; Doppler K
Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):. PubMed ID: 31454780
[TBL] [Abstract][Full Text] [Related]
4. Successful autologous hematopoietic stem cell transplantation in a refractory anti-Caspr1 antibody nodopathy.
Afanasiev V; Tsouni P; Kuntzer T; Cairoli A; Delmont E; Vallat JM; Devaux J; Théaudin M
J Peripher Nerv Syst; 2024 Mar; 29(1):116-119. PubMed ID: 38123899
[TBL] [Abstract][Full Text] [Related]
5. [The significance of autoantibodies against nodal and paranodal proteins in autoimmune nodopathies].
Ogata H
Rinsho Shinkeigaku; 2023 Nov; 63(11):715-724. PubMed ID: 37880115
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rituximab treatment in a patient with anti-neurofascin-155 IgG4 autoimmune nodopathy.
Kmezic I; Press R; Glenewinkel H; Doppler K; Appeltshauser L
J Neuroimmunol; 2024 Apr; 389():578326. PubMed ID: 38422690
[TBL] [Abstract][Full Text] [Related]
7. Neurofascin antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: from intrinsic genetic background to clinical manifestations.
Wang Z; Zhou X; Zhao N; Xie C; Zhu D; Guan Y
Neurol Sci; 2021 Jun; 42(6):2223-2233. PubMed ID: 33782779
[TBL] [Abstract][Full Text] [Related]
8. Report of a fulminant anti-pan-neurofascin-associated neuropathy responsive to rituximab and bortezomib.
Fels M; Fisse AL; Schwake C; Motte J; Athanasopoulos D; Grüter T; Spenner M; Breuer T; Starz K; Heinrich D; Grond M; Keyvani K; Appeltshauser L; Doppler K; Sommer C; Ayzenberg I; Schneider-Gold C; Gold R; Pitarokoili K; Labedi A
J Peripher Nerv Syst; 2021 Dec; 26(4):475-480. PubMed ID: 34486194
[TBL] [Abstract][Full Text] [Related]
9. Pan-Neurofascin autoimmune nodopathy - a life-threatening, but reversible neuropathy.
Appeltshauser L; Doppler K
Curr Opin Neurol; 2023 Oct; 36(5):394-401. PubMed ID: 37639464
[TBL] [Abstract][Full Text] [Related]
10. Autoantibody profile in a Malaysian cohort of chronic inflammatory demyelinating polyneuropathy.
Tan CY; Goh KJ; Oh AW; Devaux J; Shahrizaila N
Neuromuscul Disord; 2022 Mar; 32(3):255-262. PubMed ID: 35183410
[TBL] [Abstract][Full Text] [Related]
11. Anti-neurofascin autoantibody and demyelination.
Kira JI; Yamasaki R; Ogata H
Neurochem Int; 2019 Nov; 130():104360. PubMed ID: 30582947
[TBL] [Abstract][Full Text] [Related]
12. Clinical profile of autoimmune nodopathy with anti-neurofascin 186 antibody.
Liu B; Zhou L; Sun C; Wang L; Zheng Y; Hu B; Qiao K; Zhao C; Lu J; Lin J
Ann Clin Transl Neurol; 2023 Jun; 10(6):944-952. PubMed ID: 37060203
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune nodopathies, an emerging diagnostic category.
Martín-Aguilar L; Lleixà C; Pascual-Goñi E
Curr Opin Neurol; 2022 Oct; 35(5):579-585. PubMed ID: 35989582
[TBL] [Abstract][Full Text] [Related]
14. Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody.
Bai Y; Li W; Yan C; Hou Y; Wang Q
Front Immunol; 2023; 14():1121705. PubMed ID: 37056784
[TBL] [Abstract][Full Text] [Related]
15. Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response.
Bresciani L; Salvalaggio A; Vegezzi E; Visentin A; Fortuna A; Anglani M; Cacciavillani M; Masciocchi S; Scaranzin S; Carecchio M; Martinuzzi A; Gastaldi M; Briani C
J Peripher Nerv Syst; 2023 Sep; 28(3):522-527. PubMed ID: 37246762
[TBL] [Abstract][Full Text] [Related]
16. Anti-neurofascin 155 Antibody-positive Neuropathy in a Human Immunodeficiency Virus-infected Patient.
Okubo S; Mano T; Sudo A; Goto R; Yano S; Hara M; Ishiura H; Satake W; Yanagimoto S; Ogata H; Toda T
Intern Med; 2024 Feb; 63(4):565-569. PubMed ID: 37380455
[TBL] [Abstract][Full Text] [Related]
17. Different binding and pathogenic effect of neurofascin and contactin-1 autoantibodies in autoimmune nodopathies.
Hecker K; Grüner J; Hartmannsberger B; Appeltshauser L; Villmann C; Sommer C; Doppler K
Front Immunol; 2023; 14():1189734. PubMed ID: 37388725
[TBL] [Abstract][Full Text] [Related]
18. Case report: Autoimmune nodopathy with concurrent serum and CSF IgG4 anti-neurofascin 155 antibodies.
Wang W; Liu L; Zhang M; Yang R; Liu D; Yang S; Meng Q
Front Immunol; 2022; 13():1028282. PubMed ID: 36248836
[TBL] [Abstract][Full Text] [Related]
19. Nodal-paranodal antibodies in HIV-immune mediated radiculo-neuropathies: Clinical phenotypes and relevance.
Moodley K; Patel VB; Moodley AA; Bill PLA; Kajee A; Mgbachi V; Fehmi J; Rinaldi S
J Peripher Nerv Syst; 2023 Dec; 28(4):578-585. PubMed ID: 37676746
[TBL] [Abstract][Full Text] [Related]
20. Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage.
Appeltshauser L; Junghof H; Messinger J; Linke J; Haarmann A; Ayzenberg I; Baka P; Dorst J; Fisse AL; Grüter T; Hauschildt V; Jörk A; Leypoldt F; Mäurer M; Meinl E; Michels S; Motte J; Pitarokoili K; Stettner M; Villmann C; Weihrauch M; Welte GS; Zerr I; Heinze KG; Sommer C; Doppler K
Brain; 2023 May; 146(5):1932-1949. PubMed ID: 36346134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
